12 Feb 2025Open access
Inflammatory myofibroblastic tumor of the adrenal gland: A case reportPublisher siteInternational Journal of Surgery Case Reports, IgG4-Related and Inflammatory Diseases
UniversitiesSirine Elfekih
Active, last published 2026
Sirine
Elfekih
Scholar“Research profile drawn from open scholarly records.”
Institut Salah-Azaïz
Claim Your Profile1
H-index
4
Citations
Sirine has not officially claimed their profile. If you are Sirine, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
research summary for Sirine Elfekih will appear here once their profile is updated.
02 · Reach
Publication output and reach
Sirine's work has been cited 4 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
04 · Where I am
Affiliations
Affiliation on published researchInstitut Salah-AzaïzDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
3 works7 Oct 2024Open access
Papillary thyroid carcinoma in young patients in Tunisia: clinico-pathological characterization and treatment responsePublisher siteResearch Square, Thyroid Cancer Diagnosis and Treatment
25 Mar 2024Open access3cites
Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancerPublisher siteJournal of the Egyptian National Cancer Institute, Bladder and Urothelial Cancer Treatments
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Sirine?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you